Cbnaat-based detection of sars-cov-2: a laboratory perspective

On 6 November 2020 at 4:00 PM IST, Prashant Singh, PhD, Bill & Melinda Gates Foundation Project Coordinator, FIND India , will be leading an online CBNAAT training dedicated to laboratory specialists in India.

Learning objectives:

  • a detailed perspective on CBNAAT-based SARS-CoV-2 testing
  • understanding specimen collection, storage, transport and processing for the Xpert Xpress SARS-CoV-2 test on CBNAAT (GeneXpert)
  • discussing assay control strategy
  • understanding the Early Assay Termination concept and Result Interpretation
  • Troubleshooting

Thanks, Madhu
Others might like to know we have just finished a series of lab experiments to evaluate the effectiveness of two commercial sample transport media and their ability to inactivate SARS-COV-2.
Both were are able to completely deactivate this virus in 2 minutes which makes sample transfer and testing, either in labs or at the point of care, much safer and offsets the need for biosafety cabinets.
We now use one of these transport media at all of our 90 remote SARS-COV-2 testing sites across Australia. The same product can be used to deactivate TB and Flu A/B. Stability studies are underway given the harsh environments found in those remote locations - daily ambient temperatures can vary from 35-45 celsius.
Happy to forward the published results on to those who are interested.

Here is a direct link to the paper I mentioned above.
Rapid inactivation of positive SARS-COV-2 samples